We are live on
!
Find out more
Marshall Wace Portfolio holdings
AUM
$100B
1-Year Est. Return
35.1%
This Fund
S&P 500
This Quarter
Est. Return
+8.27%
1 Year Est. Return
+35.1%
3 Year Est. Return
+111.04%
5 Year Est. Return
+146.93%
10 Year Est. Return
+631.22%
AUM
$21.8B
AUM Growth
+$3.36B
(+18%)
Cap. Flow
+$2.78B
Cap. Flow
% of AUM
12.74%
Top 10 Holdings %
Top 10 Hldgs %
12.04%
Holding
3,109
New
1,280
Increased
559
Reduced
519
Closed
699
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
PARA
Paramount Global Class B
PARA
|
+$363M |
| 2 |
Tencent Music
TME
|
+$184M |
| 3 |
FTCH
Farfetch Limited Class A Ordinary Shares
FTCH
|
+$182M |
| 4 |
Baidu
BIDU
|
+$146M |
| 5 |
Gaotu Techedu
GOTU
|
+$139M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Thermo Fisher Scientific
TMO
|
+$204M |
| 2 |
Carnival Corporation Ltd
CCL
|
+$189M |
| 3 |
Zoetis
ZTS
|
+$182M |
| 4 |
Guardant Health
GH
|
+$136M |
| 5 |
Alphabet (Google) Class A
GOOGL
|
+$122M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 20.03% |
| 2 | Consumer Discretionary | 13.15% |
| 3 | Technology | 10.68% |
| 4 | Financials | 9.81% |
| 5 | Communication Services | 8.69% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
IBER.U
901
DELISTED
Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant
IBER.U
| $4.44M | 0.02% |
+450,000
| New | +$4.5M |
|
902
Essex Property Trust
ESS
$18.7B
| $4.43M | 0.02% |
16,284
-681
| -4% | -$177K |
|
903
Darden Restaurants
DRI
$23.4B
| $4.42M | 0.02% |
31,133
+26,007
| +507% | +$3.42M |
|
|
ORGN
904
DELISTED
Origin Materials
ORGN
| $4.41M | 0.02% |
14,563
-2,104
| -13% | -$693K |
|
905
Teradyne
TER
$52.4B
| $4.41M | 0.02% |
36,231
-25,387
| -41% | -$3.19M |
|
906
AerCap
AER
$23.9B
| $4.39M | 0.02% |
74,726
-70,268
| -48% | -$3.42M |
|
|
GTH
907
DELISTED
Genetron Holdings Limited ADS
GTH
| $4.38M | 0.02% |
67,986
+29,675
| +77% | +$2.04M |
|
908
Adeia
ADEA
$2.88B
| $4.37M | 0.02% |
759,062
+470,330
| +163% | +$2.71M |
|
909
Box
BOX
$4.18B
| $4.36M | 0.02% |
+189,917
| New | +$3.7M |
|
910
LG Display
LPL
$3.14B
| $4.36M | 0.02% |
436,036
+94,382
| +28% | +$941K |
|
911
Travere Therapeutics
TVTX
$5.27B
| $4.35M | 0.02% |
+174,193
| New | +$4.81M |
|
912
Century Communities
CCS
$2.03B
| $4.34M | 0.02% |
+71,973
| New | +$3.92M |
|
913
Quest Diagnostics
DGX
$25.6B
| $4.33M | 0.02% |
33,744
-27,558
| -45% | -$3.4M |
|
|
TWTR
914
CALL
DELISTED
Twitter, Inc.
TWTR
| $4.33M | 0.02% |
+68,000
| New | +$4.16M |
|
|
API
915
Agora
API
$337M
| $4.31M | 0.02% |
+85,824
| New | +$5.41M |
|
|
VRTV
916
DELISTED
VERITIV CORPORATION
VRTV
| $4.31M | 0.02% |
101,235
-11,204
| -10% | -$322K |
|
917
CoreCivic
CXW
$3.09B
| $4.28M | 0.02% |
+473,212
| New | +$3.64M |
|
918
Phathom Pharmaceuticals
PHAT
$953M
| $4.28M | 0.02% |
113,885
-4,764
| -4% | -$199K |
|
919
CALL
Microsoft
MSFT
$2.89T
| $4.27M | 0.02% |
+18,100
| New | +$4.2M |
|
|
TRIL
920
DELISTED
Trillium Therapeutics Inc.
TRIL
| $4.26M | 0.02% |
396,945
+372,463
| +1,521% | +$4.61M |
|
|
SNP
921
DELISTED
CHINA PETROLEUM & CHEMICAL CORPORATION ADS (REP 100 ORDINARY H SHARES)
SNP
| $4.26M | 0.02% |
80,825
-61,095
| -43% | -$3.19M |
|
|
IMGN
922
DELISTED
Immunogen Inc
IMGN
| $4.24M | 0.02% |
+523,087
| New | +$4.27M |
|
923
Manulife Financial
MFC
$73.2B
| $4.23M | 0.02% |
196,695
+48,645
| +33% | +$969K |
|
924
CALL
PayPal
PYPL
$49.5B
| $4.22M | 0.02% |
+17,400
| New | +$4.39M |
|
|
BLTS
925
DELISTED
Bright Lights Acquisition Corp. Class A Common Stock
BLTS
| $4.22M | 0.02% |
+439,992
| New | +$4.32M |
|
Similar funds
Marshall Wace's Q1 2021 Portfolio in Review
As of Q1 2021, Marshall Wace held 3,109 positions worth $21.8B, up 18% from $18.5B the previous quarter. Its ten largest holdings account for 12% of the portfolio.
Marshall Wace deployed $2.78B of net new capital in Q1 2021, opening 1,280 new positions and adding to 559 existing holdings. Its largest new stake was Paramount Global Class B: 5,936,494 shares worth $268M.
By sector, the portfolio is most concentrated in Healthcare at 20% of assets, down from 28% a quarter earlier, followed by Consumer Discretionary and Technology.
On the sell side, the largest reduction was Thermo Fisher Scientific, an estimated $204M trimmed.
- Marshall Wace's largest Q1 2021 buy was Paramount Global Class B: 5,936,494 shares worth $268M.
- Marshall Wace added most to Farfetch Limited Class A Ordinary Shares in Q1 2021, an estimated $182M increase.
- Marshall Wace's biggest Q1 2021 reduction was Thermo Fisher Scientific, cutting an estimated $204M.
- Marshall Wace fully exited Vanguard Intermediate-Term Corporate Bond ETF in Q1 2021, selling an estimated $76.2M.
- Marshall Wace's ten largest holdings make up 12% of its $21.8B portfolio in Q1 2021.
- Marshall Wace opened 1,280 new positions and closed 699 in Q1 2021.
- Marshall Wace's portfolio value rose 18% quarter-over-quarter to $21.8B.
Based on Marshall Wace's 13F filing for Q1 2021, filed 17 May 2021.